Literature DB >> 22972799

New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates.

Jotam Pasipanodya, Shashikant Srivastava, Tawanda Gumbo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22972799      PMCID： PMC3457406          DOI： 10.1128/AAC.00976-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  5 in total

1.  Wild-type MIC distributions must be considered to set clinically meaningful susceptibility testing breakpoints for all bacterial pathogens, including Mycobacterium tuberculosis.

Authors:  Kristian Angeby; Christian G Giske; Pontus Juréen; Thomas Schön; Jotam G Pasipanodya; Tawando Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2011-09       Impact factor: 5.191

2.  Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis.

Authors:  D A Williamson; S A Roberts; J E Bower; R Vaughan; S Newton; O Lowe; C A Lewis; J T Freeman
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

3.  Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.

Authors:  G L Drusano; S L Preston; C Hardalo; R Hare; C Banfield; D Andes; O Vesga; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

5.  Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis.

Authors:  Emmanuel Chigutsa; Sandra Meredith; Lubbe Wiesner; Nesri Padayatchi; Joe Harding; Prashini Moodley; William R Mac Kenzie; Marc Weiner; Helen McIlleron; Carl M J Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191
  5 in total
  10 in total

Review 1.  Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.

Authors:  Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India.

Authors:  Agibothu Kupparam Hemanth Kumar; Alok Kumar; Thiruvengadam Kannan; Rakesh Bhatia; Dipti Agarwal; Santosh Kumar; Rajeshwar Dayal; Sheo Pratap Singh; Geetha Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 4.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

5.  A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid.

Authors:  Koné Kaniga; Daniela M Cirillo; Sven Hoffner; Nazir A Ismail; Devinder Kaur; Nacer Lounis; Beverly Metchock; Gaby E Pfyffer; Amour Venter
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

Review 6.  A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.

Authors:  Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Tania Thomas; Soumya Swaminathan; Eric Nuermberger; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2016-11-01       Impact factor: 9.079

7.  Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru.

Authors:  Zully M Puyén; David Santos-Lázaro; Aiko N Vigo; Jorge Coronel; Miriam J Alarcón; Vidia V Cotrina; David A J Moore
Journal:  BMC Infect Dis       Date:  2022-08-24       Impact factor: 3.667

8.  Prevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.

Authors:  Tichaona Sagonda; Lucy Mupfumi; Rumbidzai Manzou; Beauty Makamure; Mqondisi Tshabalala; Lovemore Gwanzura; Peter Mason; Reggie Mutetwa
Journal:  Tuberc Res Treat       Date:  2014-05-20

9.  Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.

Authors:  Chawangwa Modongo; Jotam G Pasipanodya; Beki T Magazi; Shashikant Srivastava; Nicola M Zetola; Scott M Williams; Giorgio Sirugo; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 10.  The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes.

Authors:  Andrew D McCallum; Derek J Sloan
Journal:  Int J Pharmacokinet       Date:  2017-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.